CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | PCB138 |
|
Accession: | CHEBI:165219
|
browse the term
|
Synonyms: | exact_synonym: | 1,2,3-trichloro-4-(2,4,5-trichlorophenyl)benzene |
| related_synonym: | Formula=C12H4Cl6; InChI=1S/C12H4Cl6/c13-7-2-1-5(11(17)12(7)18)6-3-9(15)10(16)4-8(6)14/h1-4H; InChIKey=RPUMZMSNLZHIGZ-UHFFFAOYSA-N; SMILES=ClC1=C(C=2C(Cl)=CC(Cl)=C(Cl)C2)C=CC(Cl)=C1Cl |
| xref: | CAS:35065-28-2; Chemspider:33984 |
| xref_mesh: | MESH:C029790 |
|
|
|
G |
Abca13 |
ATP binding cassette subfamily A member 13 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ABCA13 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:83,873,397...84,376,138
Ensembl chr14:83,873,940...84,375,075
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
affects expression |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl affects the expression of ABCB11 mRNA |
CTD |
PMID:21703328 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ABCB1A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
EXP |
[2,5,2',5'-tetrachlorobiphenyl co-treated with 2,2',3,5',6-pentachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,3,3',4',6-pentachlorobiphenyl co-treated with 2,3',4,4',5-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl] results in increased expression of ABCC3 mRNA |
CTD |
PMID:29142165 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abhd1 |
abhydrolase domain containing 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABHD1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:25,422,526...25,427,514
Ensembl chr 6:25,422,526...25,427,514
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABLIM1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969
|
|
G |
Abr |
ABR activator of RhoGEF and GTPase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ABR mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:61,262,516...61,461,331
Ensembl chr10:61,262,516...61,461,505
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACACB mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ACADSB mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
|
|
G |
Acbd5 |
acyl-CoA binding domain containing 5 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ACBD5 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr17:85,206,178...85,248,909
Ensembl chr17:85,206,303...85,248,215
|
|
G |
Acer1 |
alkaline ceramidase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACER1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:1,794,340...1,824,432
Ensembl chr 9:1,793,139...1,824,434
|
|
G |
Ache |
acetylcholinesterase |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ACHE mRNA |
CTD |
PMID:23829299 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ACIN1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001
|
|
G |
Acly |
ATP citrate lyase |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ACLY protein |
CTD |
PMID:21673325 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACOT4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acox3 |
acyl-CoA oxidase 3, pristanoyl |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACOX3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:75,133,986...75,176,767
Ensembl chr14:75,094,676...75,176,205
|
|
G |
Acp7 |
acid phosphatase 7, tartrate resistant |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACP7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:83,896,485...83,923,436
Ensembl chr 1:83,898,153...83,920,634
|
|
G |
Acrbp |
acrosin binding protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ACRBP mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:157,851,149...157,864,211
Ensembl chr 4:157,841,841...157,864,213
|
|
G |
Acsl6 |
acyl-CoA synthetase long-chain family member 6 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACSL6 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757
|
|
G |
Acss3 |
acyl-CoA synthetase short-chain family member 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACSS3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:42,241,261...42,450,209
Ensembl chr 7:42,242,652...42,450,230
|
|
G |
Actbl2 |
actin, beta-like 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ACTBL2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:42,858,020...42,860,767
Ensembl chr 2:42,858,020...42,860,767
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ACTC1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:100,811,987...100,817,523
Ensembl chr 3:100,811,987...100,817,523
|
|
G |
Actr3b |
actin related protein 3B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ACTR3B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:9,261,631...9,355,496
Ensembl chr 4:9,262,233...9,355,441
|
|
G |
Acvr2b |
activin A receptor type 2B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ACVR2B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADAM12 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adam22 |
ADAM metallopeptidase domain 22 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADAM22 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962
|
|
G |
Adam32 |
ADAM metallopeptidase domain 32 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADAM32 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:67,102,384...67,212,163
Ensembl chr16:67,102,320...67,212,161
|
|
G |
Adam8 |
ADAM metallopeptidase domain 8 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADAM8 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:194,776,559...194,789,330
Ensembl chr 1:194,770,060...194,788,801
|
|
G |
Adamts7 |
ADAM metallopeptidase with thrombospondin type 1 motif, 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADAMTS7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:90,704,727...90,744,333
Ensembl chr 8:90,704,727...90,744,328
|
|
G |
Adat2 |
adenosine deaminase, tRNA-specific 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADAT2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:7,954,520...7,975,254
Ensembl chr 1:7,954,631...7,975,251
|
|
G |
Adcy10 |
adenylate cyclase 10 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADCY10 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:77,747,752...77,833,952
Ensembl chr13:77,768,468...77,833,951
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADGRF5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968
|
|
G |
Adgrg3 |
adhesion G protein-coupled receptor G3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADGRG3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:9,972,425...10,001,118
Ensembl chr19:9,972,430...10,001,123
|
|
G |
Adgrl4 |
adhesion G protein-coupled receptor L4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADGRL4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:240,354,909...240,457,231
Ensembl chr 2:240,354,941...240,457,225
|
|
G |
Adhfe1 |
alcohol dehydrogenase, iron containing, 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADHFE1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:9,705,966...9,732,580
Ensembl chr 5:9,705,970...9,732,517
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
affects expression multiple interactions |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl affects the expression of ADIPOQ mRNA [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ADIPOQ mRNA |
CTD |
PMID:21703328 PMID:25510870 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adm2 |
adrenomedullin 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ADM2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:120,393,179...120,394,965
Ensembl chr 7:120,393,179...120,396,331
|
|
G |
Adrm1 |
ADRM1 26S proteasome ubiquitin receptor |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ADRM1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 3:167,265,435...167,270,197
Ensembl chr 3:167,265,296...167,270,195
|
|
G |
Afap1 |
actin filament associated protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AFAP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:74,743,322...74,856,300
Ensembl chr14:74,743,320...74,856,263
|
|
G |
Agap2 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AGAP2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:62,897,282...62,914,295
Ensembl chr 7:62,897,282...62,914,295
|
|
G |
Agbl2 |
AGBL carboxypeptidase 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AGBL2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:76,764,893...76,800,071
Ensembl chr 3:76,764,238...76,800,214
|
|
G |
Ago4 |
argonaute RISC component 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AGO4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:138,780,446...138,825,898
Ensembl chr 5:138,783,069...138,825,632
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AGTR1A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agxt2 |
alanine-glyoxylate aminotransferase 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AGXT2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:59,336,252...59,377,664
Ensembl chr 2:59,336,283...59,377,926
|
|
G |
Ahcy |
adenosylhomocysteinase |
multiple interactions increases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AHCY mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of AHCY protein |
CTD |
PMID:21673325 PMID:25510870 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl promotes the reaction [AHR protein results in increased expression of CYP1A2]; [3,4,3',4'-tetrachlorobiphenyl co-treated with 3,4,5,3',4'-pentachlorobiphenyl co-treated with 3,4,5,3',4',5'-hexachlorobiphenyl co-treated with 2,3,3',4,4'-pentachlorobiphenyl co-treated with 2,3',4,4',5-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] promotes the reaction [AHR protein results in increased expression of CYP1A2 mRNA]; [AHR protein co-treated with CYP1A2 protein] affects the susceptibility to [3,4,3',4'-tetrachlorobiphenyl co-treated with 3,4,5,3',4'-pentachlorobiphenyl co-treated with 3,4,5,3',4',5'-hexachlorobiphenyl co-treated with 2,3,3',4,4'-pentachlorobiphenyl co-treated with 2,3',4,4',5-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] |
CTD |
PMID:20961953 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aipl1 |
aryl hydrocarbon receptor-interacting protein-like 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AIPL1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:56,655,693...56,664,922
Ensembl chr10:56,655,693...56,664,922
|
|
G |
Ajap1 |
adherens junctions associated protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AJAP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:163,907,846...164,021,004
Ensembl chr 5:163,907,847...164,020,317
|
|
G |
Ak1 |
adenylate kinase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AK1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Ak5 |
adenylate kinase 5 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of AK5 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Akap10 |
A-kinase anchoring protein 10 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKAP10 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:46,545,371...46,608,730
Ensembl chr10:46,551,532...46,608,769
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
multiple interactions increases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AKAP9 mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of AKAP9 mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKR1B7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of AKT2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AKT3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708
|
|
G |
Aktip |
AKT interacting protein |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of AKTIP mRNA |
CTD |
PMID:23829299 |
|
NCBI chr19:15,866,811...15,877,123
Ensembl chr19:15,866,928...15,886,663
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ALDH18A1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ALDH6A1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ALDOC mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alg13 |
ALG13, UDP-N-acetylglucosaminyltransferase subunit |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ALG13 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:107,906,320...107,968,232
Ensembl chr X:107,885,093...107,942,695
|
|
G |
Alkbh8 |
alkB homolog 8, tRNA methyltransferase |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ALKBH8 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 6:378,779...449,382
Ensembl chr 6:378,100...452,165
|
|
G |
Als2 |
alsin Rho guanine nucleotide exchange factor ALS2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ALS2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:60,613,182...60,686,394
Ensembl chr 9:60,613,167...60,670,737
|
|
G |
Ambn |
ameloblastin |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of AMBN mRNA |
CTD |
PMID:23829299 |
|
NCBI chr14:19,601,761...19,614,382
Ensembl chr14:19,601,702...19,614,393
|
|
G |
Amer3 |
APC membrane recruitment protein 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AMER3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:36,790,355...36,802,341
Ensembl chr 9:36,790,932...36,802,419
|
|
G |
Amh |
anti-Mullerian hormone |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AMH mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Amph |
amphiphysin |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of AMPH protein |
CTD |
PMID:21673325 |
|
NCBI chr17:45,739,385...45,982,905
Ensembl chr17:45,739,395...45,983,315
|
|
G |
Angptl3 |
angiopoietin-like 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Ank1 |
ankyrin 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANK1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:68,876,294...69,054,963
Ensembl chr16:68,877,504...69,054,759
|
|
G |
Ank3 |
ankyrin 3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ANK3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
|
|
G |
Ankle1 |
ankyrin repeat and LEM domain containing 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ANKLE1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:18,076,413...18,082,356
Ensembl chr16:18,076,492...18,083,729
|
|
G |
Ankrd12 |
ankyrin repeat domain 12 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKRD12 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:105,583,273...105,687,957
Ensembl chr 9:105,584,065...105,687,911
|
|
G |
Ankrd22 |
ankyrin repeat domain 22 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKRD22 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:231,639,035...231,670,537
Ensembl chr 1:231,639,314...231,670,381
|
|
G |
Ankrd34a |
ankyrin repeat domain 34A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKRD34A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:184,129,830...184,135,075
Ensembl chr 2:184,129,238...184,135,116
|
|
G |
Ankrd34b |
ankyrin repeat domain 34B |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ANKRD34B mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 2:23,651,083...23,668,041
Ensembl chr 2:23,651,474...23,668,030
|
|
G |
Ankrd40 |
ankyrin repeat domain 40 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKRD40 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:79,282,075...79,295,322
Ensembl chr10:79,282,075...79,295,320 Ensembl chr10:79,282,075...79,295,320
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANKS1B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693
|
|
G |
Ano10 |
anoctamin 10 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO10 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670
|
|
G |
Ano3 |
anoctamin 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ANO3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154
|
|
G |
Anp32a |
acidic nuclear phosphoprotein 32 family member A |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ANP32A protein |
CTD |
PMID:21673325 |
|
NCBI chr 8:62,829,099...62,865,443
Ensembl chr 8:62,827,456...62,865,443
|
|
G |
Antxr2 |
ANTXR cell adhesion molecule 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ANTXR2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:11,541,718...11,682,110
Ensembl chr14:11,541,772...11,682,094
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ANXA3 protein |
CTD |
PMID:21673325 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Anxa7 |
annexin A7 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ANXA7 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385
|
|
G |
Ap4e1 |
adaptor related protein complex 4 subunit epsilon 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AP4E1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:114,272,997...114,339,484
Ensembl chr 3:114,272,956...114,336,752
|
|
G |
Apc2 |
APC regulator of WNT signaling pathway 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of APC2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 7:9,392,336...9,414,364
Ensembl chr 7:9,392,336...9,414,310
|
|
G |
Apoa1 |
apolipoprotein A1 |
affects expression |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl affects the expression of APOA1 mRNA |
CTD |
PMID:21703328 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apobr |
apolipoprotein B receptor |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of APOBR mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:181,169,019...181,173,206
Ensembl chr 1:181,168,916...181,173,528
|
|
G |
Apod |
apolipoprotein D |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of APOD mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
Apol2 |
apolipoprotein L2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of APOL8 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:109,331,367...109,338,632
Ensembl chr 7:109,331,392...109,338,558
|
|
G |
Apool |
apolipoprotein O-like |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of APOOL mRNA |
CTD |
PMID:23829299 |
|
NCBI chr X:77,377,723...77,443,672
Ensembl chr X:77,377,781...77,443,900
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180 co-treated with APP protein modified form] results in decreased expression of DLG4 protein; [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180 co-treated with APP protein modified form] results in decreased expression of SYP protein |
CTD |
PMID:26480858 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AQP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of AQP3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Ar |
androgen receptor |
decreases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of AR protein 2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; 2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Metribolone results in increased activity of AR protein] 2,2',3',4,4',5-hexachlorobiphenyl analog inhibits the reaction [Dihydrotestosterone binds to AR protein]; [2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AR mRNA |
CTD |
PMID:11906248 PMID:18324785 PMID:21190954 PMID:21357386 PMID:21673325 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arfgap1 |
ARF GTPase activating protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARFGAP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:168,084,560...168,099,948
Ensembl chr 3:168,084,614...168,099,933
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARHGAP11A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559
|
|
G |
Arhgap20 |
Rho GTPase activating protein 20 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ARHGAP20 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739
|
|
G |
Arhgap26 |
Rho GTPase activating protein 26 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARHGAP26 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:30,835,806...31,237,945
Ensembl chr18:30,838,671...31,235,194
|
|
G |
Arhgef10 |
Rho guanine nucleotide exchange factor 10 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ARHGEF10 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr16:74,647,147...74,738,784
Ensembl chr16:74,647,153...74,738,173
|
|
G |
Arhgef15 |
Rho guanine nucleotide exchange factor 15 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARHGEF15 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:53,650,521...53,663,269
Ensembl chr10:53,650,553...53,663,913
|
|
G |
Arhgef33 |
Rho guanine nucleotide exchange factor 33 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARHGEF33 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:14,582,922...14,715,014
Ensembl chr 6:14,551,495...14,725,292
|
|
G |
Arhgef37 |
Rho guanine nucleotide exchange factor 37 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARHGEF37 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:54,935,256...55,001,017
Ensembl chr18:54,949,110...55,000,669
|
|
G |
Arhgef38 |
Rho guanine nucleotide exchange factor 38 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARHGEF38 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:221,610,212...221,739,841
Ensembl chr 2:221,613,070...221,740,079
|
|
G |
Arhgef39 |
Rho guanine nucleotide exchange factor 39 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARHGEF39 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:57,752,509...57,756,079
Ensembl chr 5:57,752,509...57,756,109
|
|
G |
Arhgef4 |
Rho guanine nucleotide exchange factor 4 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ARHGEF4 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 9:36,861,800...37,005,079
Ensembl chr 9:36,861,835...37,005,075
|
|
G |
Arhgef5 |
Rho guanine nucleotide exchange factor 5 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ARHGEF5 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 4:72,087,205...72,112,316
Ensembl chr 4:72,087,247...72,111,254
|
|
G |
Arhgef7 |
Rho guanine nucleotide exchange factor 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARHGEF7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:77,671,021...77,782,593
Ensembl chr16:77,671,023...77,782,697
|
|
G |
Arid1a |
AT-rich interaction domain 1A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARID1A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:145,908,173...145,981,552
Ensembl chr 5:145,908,181...145,985,564
|
|
G |
Arih2 |
ariadne RBR E3 ubiquitin protein ligase 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ARIH2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 8:109,296,738...109,355,909
Ensembl chr 8:109,296,738...109,355,852
|
|
G |
Ark2c |
arkadia C-terminal like ring finger ubiquitin ligase 2C |
decreases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ARK2C mRNA [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARK2C mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr18:70,984,566...71,100,836
Ensembl chr18:70,989,731...71,100,836
|
|
G |
Arl16 |
ARF like GTPase 16 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARL16 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:105,737,455...105,739,631
Ensembl chr10:105,737,154...105,739,824
|
|
G |
Arpc2 |
actin related protein 2/3 complex, subunit 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ARPC2 protein |
CTD |
PMID:21673325 |
|
NCBI chr 9:75,820,782...75,851,471
Ensembl chr 9:75,820,770...75,851,471
|
|
G |
Arsj |
arylsulfatase family, member J |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ARSJ mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:214,774,631...214,854,614
Ensembl chr 2:214,774,654...214,854,612
|
|
G |
Art4 |
ADP-ribosyltransferase 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ART4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:169,740,331...169,751,571
Ensembl chr 4:169,740,331...169,750,665
|
|
G |
Arvcf |
ARVCF, delta catenin family member |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ARVCF mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:82,588,137...82,645,832
Ensembl chr11:82,587,881...82,645,805
|
|
G |
Asb16 |
ankyrin repeat and SOCS box-containing 16 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASB16 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:87,225,976...87,233,078
Ensembl chr10:87,225,912...87,233,078
|
|
G |
Ascc1 |
activating signal cointegrator 1 complex subunit 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ASCC1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr20:27,941,053...28,031,272
Ensembl chr20:27,941,283...28,031,272
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ASF1B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Asgr1 |
asialoglycoprotein receptor 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ASGR1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:54,775,727...54,779,642
Ensembl chr10:54,776,024...54,779,631
|
|
G |
Asic2 |
acid sensing ion channel subunit 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASIC2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:65,870,592...66,940,577
Ensembl chr10:65,870,594...66,940,424
|
|
G |
Asic4 |
acid sensing ion channel subunit family member 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASIC4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900
|
|
G |
Aspa |
aspartoacylase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASPA mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:57,891,704...57,945,267
Ensembl chr10:57,892,104...57,945,272
|
|
G |
Asph |
aspartate-beta-hydroxylase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ASPH mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Aspm |
assembly factor for spindle microtubules |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ASPM mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
|
|
G |
Asxl3 |
ASXL transcriptional regulator 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ASXL3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:13,593,529...13,766,324
Ensembl chr18:13,593,985...13,762,427
|
|
G |
Atad2b |
ATPase family, AAA domain containing 2B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATAD2B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:27,914,546...28,070,103
Ensembl chr 6:27,912,862...28,067,047
|
|
G |
Atad5 |
ATPase family, AAA domain containing 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATAD5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:65,070,682...65,118,489
Ensembl chr10:65,070,689...65,117,845
|
|
G |
Ate1 |
arginyltransferase 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ATE1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:184,961,548...185,081,112
Ensembl chr 1:184,963,562...185,080,908
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATM mRNA; [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATM protein |
CTD |
PMID:25510870 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atoh1 |
atonal bHLH transcription factor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATOH1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:93,912,068...93,914,163
Ensembl chr 4:93,912,068...93,914,154
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ATP1A1 protein |
CTD |
PMID:21673325 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ATP1A2 protein |
CTD |
PMID:21673325 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ATP1A3 protein |
CTD |
PMID:21673325 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ATP1B1 protein |
CTD |
PMID:21673325 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ATP2A2 protein |
CTD |
PMID:21673325 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ATP2B1 mRNA; 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ATP2B1 protein |
CTD |
PMID:21673325 PMID:23829299 |
|
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp2b2 |
ATPase plasma membrane Ca2+ transporting 2 |
increases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ATP2B2 protein [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B2 mRNA |
CTD |
PMID:21673325 PMID:25510870 |
|
NCBI chr 4:146,894,602...147,208,060
Ensembl chr 4:146,896,332...147,140,665
|
|
G |
Atp2b3 |
ATPase plasma membrane Ca2+ transporting 3 |
multiple interactions increases expression decreases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B3 mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ATP2B3 protein 2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ATP2B3 mRNA |
CTD |
PMID:21673325 PMID:23829299 PMID:25510870 |
|
NCBI chr X:151,216,483...151,289,069
Ensembl chr X:151,216,507...151,286,775
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP2B4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ATP5F1A protein |
CTD |
PMID:21673325 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5f1e |
ATP synthase F1 subunit epsilon |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5F1E mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450
|
|
G |
Atp5mc1 |
ATP synthase membrane subunit c locus 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5MC1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124 Ensembl chr10:81,023,925...81,027,124
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5MF mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp5mg |
ATP synthase membrane subunit G |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5MG mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:45,225,680...45,233,630
Ensembl chr 8:45,225,686...45,233,559
|
|
G |
Atp5mk |
ATP synthase membrane subunit K |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP5MK mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:245,973,910...245,980,702
Ensembl chr 1:245,973,914...245,980,761 Ensembl chr10:245,973,914...245,980,761
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ATP5PD mRNA; 2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ATP5PD protein |
CTD |
PMID:21673325 PMID:23829299 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atp6ap1l |
ATPase H+ transporting accessory protein 1 like |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP6AP1L mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:22,037,542...22,079,376
Ensembl chr 2:22,037,563...22,065,038
|
|
G |
Atp6v1g2 |
ATPase H+ transporting V1 subunit G2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ATP6V1G2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr20:3,587,681...3,591,309
Ensembl chr20:3,587,686...3,590,481
|
|
G |
Atp6v1g3 |
ATPase H+ transporting V1 subunit G3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ATP6V1G3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:49,800,256...49,825,247
Ensembl chr13:49,794,222...49,825,247
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATR mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Atxn7l2 |
ataxin 7-like 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ATXN7L2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:195,838,920...195,847,339
Ensembl chr 2:195,838,981...195,847,315
|
|
G |
Auh |
AU RNA binding methylglutaconyl-CoA hydratase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AUH mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:12,329,522...12,424,882
Ensembl chr17:12,329,524...12,424,896
|
|
G |
Aurka |
aurora kinase A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AURKA mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AURKB mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AVPI1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154
|
|
G |
Azgp1 |
alpha-2-glycoprotein 1, zinc-binding |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of AZGP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091
|
|
G |
B3gat1 |
beta-1,3-glucuronyltransferase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:25,087,123...25,114,692
Ensembl chr 8:25,087,547...25,113,395
|
|
G |
B3gat2 |
beta-1,3-glucuronyltransferase 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of B3GAT2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:26,167,174...26,250,153
Ensembl chr 9:26,167,174...26,250,153
|
|
G |
B4galnt4 |
beta-1,4-N-acetyl-galactosaminyl transferase 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of B4GALNT4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:196,171,394...196,182,294
Ensembl chr 1:196,171,394...196,182,294
|
|
G |
Babam2 |
BRISC and BRCA1 A complex member 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BABAM2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:24,369,021...24,788,416
Ensembl chr 6:24,369,022...24,833,951
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BARD1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Barhl1 |
BarH-like homeobox 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BARHL1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:12,241,327...12,248,649
Ensembl chr 3:12,241,327...12,248,649
|
|
G |
Barx2 |
BARX homeobox 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BARX2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:30,251,132...30,319,105
Ensembl chr 8:30,251,132...30,319,013
|
|
G |
Baz1a |
bromodomain adjacent to zinc finger domain, 1A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BAZ1A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:72,389,701...72,512,516
Ensembl chr 6:72,389,703...72,512,459
|
|
G |
Baz2b |
bromodomain adjacent to zinc finger domain, 2B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BAZ2B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:44,384,282...44,681,619
Ensembl chr 3:44,385,474...44,592,908
|
|
G |
Bbs7 |
Bardet-Biedl syndrome 7 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of BBS7 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 2:119,434,760...119,474,665
Ensembl chr 2:119,434,760...119,474,396
|
|
G |
Bbx |
BBX high mobility group box domain containing |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BBX mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:50,381,249...50,628,934
Ensembl chr11:50,381,247...50,623,251
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of BCL2L1 protein]; 2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [TNF protein results in decreased expression of BCL2L1 protein] 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of BCL2L1 protein |
CTD |
PMID:29704545 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l14 |
Bcl2-like 14 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BCL2L14 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:167,217,561...167,258,723
Ensembl chr 4:167,219,871...167,258,086
|
|
G |
Bend4 |
BEN domain containing 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BEND4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:40,753,048...40,788,686
Ensembl chr14:40,753,077...40,783,504
|
|
G |
Bend7 |
BEN domain containing 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BEND7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:73,483,212...73,566,221
Ensembl chr17:73,485,282...73,567,559
|
|
G |
Bin1 |
bridging integrator 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of BIN1 protein |
CTD |
PMID:21673325 |
|
NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BIRC3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of BIRC5 protein]; 2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [TNF protein results in decreased expression of BIRC5 protein]; [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BIRC5 mRNA |
CTD |
PMID:25510870 PMID:29704545 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bltp3a |
bridge-like lipid transfer protein family member 3A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BLTP3A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr20:5,910,261...5,954,641
Ensembl chr20:5,910,260...5,952,404
|
|
G |
Blzf1 |
basic leucine zipper nuclear factor 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of BLZF1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr13:76,641,757...76,656,977
Ensembl chr13:76,641,515...76,656,999
|
|
G |
Bmal2 |
basic helix-loop-helix ARNT like 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BMAL2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of BMP1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bms1 |
BMS1 ribosome biogenesis factor |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of BMS1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 4:151,558,163...151,595,187
Ensembl chr 4:151,558,163...151,595,127
|
|
G |
Bnip2 |
BCL2 interacting protein 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BNIP2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:70,640,436...70,661,782
Ensembl chr 8:70,640,445...70,675,590
|
|
G |
Bora |
bora, aurora kinase A activator |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BORA mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
|
|
G |
Borcs8 |
BLOC-1 related complex subunit 8 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of BORCS8 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr16:19,274,305...19,280,969
Ensembl chr16:19,274,023...19,280,339
|
|
G |
Bpifb6 |
BPI fold containing family B, member 6 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BPIFB6 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:142,381,478...142,395,304
Ensembl chr 3:142,381,374...142,395,308
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Estradiol results in increased expression of BRCA1 mRNA] |
CTD |
PMID:12473173 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 mRNA; [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRCA2 protein |
CTD |
PMID:25510870 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Brd8 |
bromodomain containing 8 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRD8 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:26,204,892...26,229,999
Ensembl chr18:26,181,732...26,229,884
|
|
G |
Bricd5 |
BRICHOS domain containing 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BRICD5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:13,498,726...13,500,259
Ensembl chr10:13,498,381...13,500,259
|
|
G |
Brinp3 |
BMP/retinoic acid inducible neural specific 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BRINP3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:58,413,883...58,846,828
Ensembl chr13:58,413,883...58,846,770
|
|
G |
Brip1 |
BRCA1 interacting DNA helicase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BRIP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:70,907,266...71,031,502
Ensembl chr10:70,907,371...71,030,324
|
|
G |
Brwd3 |
bromodomain and WD repeat domain containing 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BRWD3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:73,768,343...73,861,643
Ensembl chr X:73,774,340...73,861,622
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BTG1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BUB1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of BUB1B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C1qtnf4 |
C1q and TNF related 4 |
multiple interactions decreases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of C1QTNF4 mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of C1QTNF4 mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr 3:76,854,368...76,872,991
Ensembl chr 3:76,857,735...76,874,139
|
|
G |
C3 |
complement C3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of C3 protein |
CTD |
PMID:21673325 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C5ar2 |
complement C5a receptor 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of C5AR2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:76,930,381...76,945,432
Ensembl chr 1:76,930,383...76,959,517
|
|
G |
C7 |
complement C7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of C7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:54,088,116...54,165,102
Ensembl chr 2:54,088,116...54,158,535
|
|
G |
C8b |
complement C8 beta chain |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of C8B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:119,535,009...119,572,565
Ensembl chr 5:119,535,146...119,572,565
|
|
G |
Cacna1f |
calcium voltage-gated channel subunit alpha1 F |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CACNA1F mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:65,800,059...65,831,246
Ensembl chr 1:65,800,355...65,831,006
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions increases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CALB1 mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CALB1 protein |
CTD |
PMID:21673325 PMID:25510870 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Calb2 |
calbindin 2 |
multiple interactions increases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CALB2 mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CALB2 protein |
CTD |
PMID:21673325 PMID:25510870 |
|
NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
|
|
G |
Calm3 |
calmodulin 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CALM3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:77,590,668...77,597,776
Ensembl chr 1:77,589,230...77,592,207
|
|
G |
Calu |
calumenin |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CALU mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Caly |
calcyon neuron-specific vesicular protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CALY mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:194,862,671...194,873,861
Ensembl chr 1:194,862,672...194,873,551
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMK2A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMK2B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMK2N1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAMKK2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Cap2 |
cyclase associated actin cytoskeleton regulatory protein 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAP2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:18,054,234...18,203,453
Ensembl chr17:18,054,431...18,203,373
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CAPRIN1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 3:90,152,305...90,230,447
Ensembl chr 3:90,153,620...90,230,502
|
|
G |
Capza1 |
capping actin protein of muscle Z-line subunit alpha 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CAPZA1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:192,319,696...192,364,755
Ensembl chr 2:192,319,702...192,364,480
|
|
G |
Car12 |
carbonic anhydrase 12 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAR12 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car7 |
carbonic anhydrase 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAR7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:429,063...438,478
Ensembl chr19:429,075...438,467
|
|
G |
Car8 |
carbonic anhydrase 8 |
increases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CAR8 protein [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CAR8 mRNA |
CTD |
PMID:21673325 PMID:25510870 |
|
NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374
|
|
G |
Cartpt |
CART prepropeptide |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CARTPT mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein] |
CTD |
PMID:29704545 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casz1 |
castor zinc finger 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CASZ1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:159,243,965...159,393,935
Ensembl chr 5:159,243,995...159,393,400
|
|
G |
Catsperd |
cation channel sperm associated auxiliary subunit delta |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CATSPERD mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:1,459,967...1,498,342
Ensembl chr 9:1,460,001...1,498,344
|
|
G |
Catsperg |
cation channel sperm associated auxiliary subunit gamma |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CATSPERG1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:84,488,728...84,519,495
Ensembl chr 1:84,488,730...84,519,559
|
|
G |
Cbfa2t3 |
CBFA2/RUNX1 partner transcriptional co-repressor 3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CBFA2T3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr19:50,679,897...50,750,028
Ensembl chr19:50,680,729...50,749,610
|
|
G |
Cblc |
Cbl proto-oncogene C |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CBLC mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:79,439,975...79,456,755
Ensembl chr 1:79,439,977...79,456,755
|
|
G |
Cbln4 |
cerebellin 4 precursor |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CBLN4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:160,799,587...160,807,143
Ensembl chr 3:160,799,587...160,807,143
|
|
G |
Cbx2 |
chromobox 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CBX2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:104,278,517...104,287,384
Ensembl chr10:104,278,549...104,287,383
|
|
G |
Cbx7 |
chromobox 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CBX7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973
|
|
G |
Ccdc106 |
coiled-coil domain containing 106 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CCDC106 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:68,779,882...68,783,975
Ensembl chr 1:68,779,882...68,786,846
|
|
G |
Ccdc116 |
coiled-coil domain containing 116 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCDC116 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:83,842,707...83,850,607
Ensembl chr11:83,845,557...83,850,607
|
|
G |
Ccdc148 |
coiled-coil domain containing 148 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC148 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:43,356,885...43,631,999
Ensembl chr 3:43,356,892...43,631,991
|
|
G |
Ccdc175 |
coiled-coil domain containing 175 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC175 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:90,661,948...90,745,015
Ensembl chr 6:90,662,269...90,744,963
|
|
G |
Ccdc60 |
coiled-coil domain containing 60 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC60 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:40,314,687...40,480,338
Ensembl chr12:40,314,713...40,480,225
|
|
G |
Ccdc70 |
coiled-coil domain containing 70 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC70 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:70,037,309...70,042,401
Ensembl chr16:70,037,309...70,042,339
|
|
G |
Ccdc74a |
coiled-coil domain containing 74A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC74A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:83,355,888...83,360,269
Ensembl chr11:83,355,874...83,360,378
|
|
G |
Ccdc8 |
coiled-coil domain containing 8 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCDC8 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:77,679,521...77,682,849
Ensembl chr 1:77,679,218...77,683,090
|
|
G |
Ccdc83 |
coiled-coil domain containing 83 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC83 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:144,167,993...144,225,622
Ensembl chr 1:144,167,857...144,225,656
|
|
G |
Ccdc85b |
coiled-coil domain containing 85B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC85B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:202,763,645...202,764,660
Ensembl chr 1:202,763,631...202,764,703
|
|
G |
Ccdc85c |
coiled-coil domain containing 85C |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCDC85C mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:127,113,440...127,184,328
Ensembl chr 6:127,113,442...127,184,371
|
|
G |
Ccdc92 |
coiled-coil domain containing 92 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CCDC92 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr12:31,796,102...31,823,333
Ensembl chr12:31,796,684...31,823,337
|
|
G |
Cck |
cholecystokinin |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CCK mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCL1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159
|
|
G |
Ccl19 |
C-C motif chemokine ligand 19 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CCL19 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCL2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CCL21 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCL28 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CCL3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CCL5 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccna1 |
cyclin A1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNA1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNA2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNB1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNB2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCND2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNE1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccnf |
cyclin F |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CCNF mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
affects expression |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl affects the expression of CCR2 mRNA |
CTD |
PMID:21703328 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CCT5 protein |
CTD |
PMID:21673325 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cd1d1 |
CD1d1 molecule |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD1D1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:172,423,582...172,427,089
Ensembl chr 2:172,423,582...172,427,089
|
|
G |
Cd276 |
Cd276 molecule |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD276 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:58,937,751...58,968,082
Ensembl chr 8:58,937,751...58,968,380
|
|
G |
Cd300ld |
Cd300 molecule-like family member D |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD300LD mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:100,082,957...100,115,853
Ensembl chr10:100,083,490...100,115,821
|
|
G |
Cd320 |
CD320 molecule |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CD320 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:14,626,171...14,631,976
Ensembl chr 7:14,609,146...14,631,976
|
|
G |
Cd38 |
CD38 molecule |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CD38 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd6 |
Cd6 molecule |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD6 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:207,442,873...207,481,703
Ensembl chr 1:207,442,877...207,481,634
|
|
G |
Cd70 |
Cd70 molecule |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CD70 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:2,006,563...2,009,715
Ensembl chr 9:2,006,563...2,009,715
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD80 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd8a |
CD8 subunit alpha |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CD8A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:103,365,804...103,370,041
Ensembl chr 4:103,365,804...103,370,040
|
|
G |
Cd93 |
CD93 molecule |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD93 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:135,891,859...135,898,378
Ensembl chr 3:135,891,859...135,898,378
|
|
G |
Cd96 |
CD96 molecule |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CD96 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:54,702,290...54,776,618
Ensembl chr11:54,702,290...54,776,621
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDC20 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc25b |
cell division cycle 25B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDC25B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDC25C mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc42bpa |
CDC42 binding protein kinase alpha |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDC42BPA mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:91,683,775...91,903,732
Ensembl chr13:91,684,007...91,903,732
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CDC6 mRNA [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDC6 mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca2 |
cell division cycle associated 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611
|
|
G |
Cdca3 |
cell division cycle associated 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdca5 |
cell division cycle associated 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA7L mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888
|
|
G |
Cdca8 |
cell division cycle associated 8 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDCA8 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh18 |
cadherin 18 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH18 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:72,818,076...73,820,144
Ensembl chr 2:73,345,005...73,820,138
|
|
G |
Cdh22 |
cadherin 22 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH22 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:153,845,563...153,970,630
Ensembl chr 3:153,845,787...153,970,588
|
|
G |
Cdh23 |
cadherin-related 23 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH23 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr20:28,240,643...28,622,490
Ensembl chr20:28,240,645...28,622,419
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDH5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdh7 |
cadherin 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:26,672,058...26,821,571
Ensembl chr13:26,672,484...26,819,846
|
|
G |
Cdh8 |
cadherin 8 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDH8 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:5,494,038...5,901,810
Ensembl chr19:5,494,174...5,895,669
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDK1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions affects expression |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDK2 mRNA 2,2',3',4,4',5-hexachlorobiphenyl affects the expression of CDK2 mRNA |
CTD |
PMID:21703328 PMID:25510870 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDK6 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdon |
cell adhesion associated, oncogene regulated |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CDON mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:33,775,123...33,861,635
Ensembl chr 8:33,806,183...33,859,033
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CDT1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Cecr2 |
CECR2, histone acetyl-lysine reader |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CECR2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:153,890,310...153,998,078
Ensembl chr 4:153,890,206...153,993,451
|
|
G |
Cela1 |
chymotrypsin like elastase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CELA1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:131,773,161...131,786,300
Ensembl chr 7:131,742,002...131,786,285
|
|
G |
Celf1 |
CUGBP, Elav-like family member 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CELF1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:76,924,591...76,999,429
Ensembl chr 3:76,924,613...76,999,426
|
|
G |
Celsr2 |
cadherin, EGF LAG seven-pass G-type receptor 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CELSR2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:196,029,206...196,053,848
Ensembl chr 2:196,029,434...196,053,845
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CELSR3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cemip |
cell migration inducing hyaluronidase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CEMIP mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415
|
|
G |
Cenpe |
centromere protein E |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPE mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669
|
|
G |
Cenpf |
centromere protein F |
decreases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CENPF mRNA [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPF mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cenph |
centromere protein H |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPH mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:31,896,675...31,910,179
Ensembl chr 2:31,894,667...31,910,154
|
|
G |
Cenpi |
centromere protein I |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPI mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:97,515,919...97,567,671
Ensembl chr X:97,515,972...97,567,657
|
|
G |
Cenpj |
centromere protein J |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CPAP mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:30,627,206...30,690,384
Ensembl chr15:30,627,224...30,686,791
|
|
G |
Cenpk |
centromere protein K |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPK mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:35,360,390...35,421,372
Ensembl chr 2:35,360,132...35,385,706
|
|
G |
Cenpm |
centromere protein M |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPM mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:113,748,026...113,759,296
Ensembl chr 7:113,747,516...113,764,258
|
|
G |
Cenpn |
centromere protein N |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPN mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:44,971,265...44,994,019
Ensembl chr19:44,968,308...44,994,012
|
|
G |
Cenpp |
centromere protein P |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPP mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:15,014,087...15,189,312
Ensembl chr17:15,014,058...15,189,304
|
|
G |
Cenps |
centromere protein S |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CENPS mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:159,563,917...159,573,534
|
|
G |
Cenpt |
centromere protein T |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CENPT mRNA |
CTD |
PMID:23829299 |
|
NCBI chr19:33,734,684...33,741,159
Ensembl chr19:33,734,685...33,741,142
|
|
G |
Cenpu |
centromere protein U |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CENPU mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823
|
|
G |
Cep164 |
centrosomal protein 164 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CEP164 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:46,070,901...46,134,511
Ensembl chr 8:46,071,076...46,134,336
|
|
G |
Cep295 |
centrosomal protein 295 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CEP295 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:12,156,568...12,194,542
Ensembl chr 8:12,156,554...12,194,552
|
|
G |
Cep55 |
centrosomal protein 55 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CEP55 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394
|
|
G |
Cers3 |
ceramide synthase 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CERS3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:120,316,930...120,422,926
Ensembl chr 1:120,318,212...120,422,902
|
|
G |
Cfc1 |
cripto, FRL-1, cryptic family 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CFC1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:36,742,106...36,751,931
Ensembl chr 9:36,739,071...36,751,930
|
|
G |
Cfl1 |
cofilin 1 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CFL1 protein |
CTD |
PMID:21673325 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Chac2 |
ChaC glutathione specific gamma-glutamylcyclotransferase 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CHAC2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr14:104,720,754...104,728,305
Ensembl chr14:104,720,758...104,728,301
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHAF1A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Chaf1b |
chromatin assembly factor 1 subunit B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHAF1B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070
|
|
G |
Chct1 |
CHD1 helical C-terminal domain containing 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CHCT1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:70,039,510...70,051,556
Ensembl chr10:70,039,680...70,051,542
|
|
G |
Chmp4c |
charged multivesicular body protein 4C |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CHMP4C mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 2:91,391,729...91,428,652
Ensembl chr 2:91,388,530...91,428,668
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CHN1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490
|
|
G |
Chn2 |
chimerin 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CHN2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHRM1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrna10 |
cholinergic receptor nicotinic alpha 10 subunit |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CHRNA10 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:156,487,279...156,494,277
Ensembl chr 1:156,487,279...156,491,476
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHRNA3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CHRNA7 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chst15 |
carbohydrate sulfotransferase 15 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CHST15 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:187,028,860...187,107,908
Ensembl chr 1:187,028,970...187,107,707
|
|
G |
Churc1 |
churchill domain containing 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CHURC1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:95,464,488...95,485,208
Ensembl chr 6:95,470,683...95,619,586
|
|
G |
Cib2 |
calcium and integrin binding family member 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CIB2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 8:54,930,265...54,947,157
|
|
G |
Cibar1 |
CBY1 interacting BAR domain containing 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CIBAR1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 5:25,613,993...25,632,440
Ensembl chr 5:25,614,033...25,632,489
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
increases expression |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CIDEC protein |
CTD |
PMID:29704545 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Cilp |
cartilage intermediate layer protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CILP mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:65,777,281...65,792,251
Ensembl chr 8:65,777,281...65,792,251
|
|
G |
Cimap1d |
CIMAP1 family member D |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CIMAP1D mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 7:10,049,472...10,065,626
Ensembl chr 7:10,059,589...10,065,125
|
|
G |
Cirop |
ciliated left-right organizer metallopeptidase |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CIROP mRNA |
CTD |
PMID:23829299 |
|
NCBI chr15:28,151,018...28,158,149
Ensembl chr15:28,151,019...28,158,129
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CISH mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKAP2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Ckap2l |
cytoskeleton associated protein 2-like |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKAP2L mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:116,497,186...116,524,302
Ensembl chr 3:116,498,022...116,524,366
|
|
G |
Ckap4 |
cytoskeleton-associated protein 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKAP4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914
|
|
G |
Cklf |
chemokine-like factor |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKLF mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:698,097...706,570
Ensembl chr19:698,033...706,570
|
|
G |
Ckmt1 |
creatine kinase, mitochondrial 1 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CKMT1 protein |
CTD |
PMID:21673325 |
|
NCBI chr 3:108,329,859...108,335,760
Ensembl chr 3:108,330,705...108,335,758
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CKS2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Cldn2 |
claudin 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CLDN2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Cldn4 |
claudin 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CLDN4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
|
|
G |
Clec12b |
C-type lectin domain family 12, member B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLEC12B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:162,827,462...162,843,821
Ensembl chr 4:162,827,462...162,838,946
|
|
G |
Clec5a |
C-type lectin domain containing 5A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLEC5A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:69,407,125...69,416,872
Ensembl chr 4:69,407,835...69,416,859
|
|
G |
Clec7a |
C-type lectin domain containing 7A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLEC7A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897
|
|
G |
Clhc1 |
clathrin heavy chain linker domain containing 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLHC1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:103,288,116...103,328,725
Ensembl chr14:103,288,134...103,328,715
|
|
G |
Clmp |
CXADR-like membrane protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLMP mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:41,060,527...41,168,841
Ensembl chr 8:41,060,799...41,168,838
|
|
G |
Clrn2 |
clarin 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CLRN2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:65,656,029...65,666,325
Ensembl chr14:65,656,550...65,666,193
|
|
G |
Clrn3 |
clarin 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CLRN3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:190,319,025...190,334,648
Ensembl chr 1:190,319,026...190,334,648
|
|
G |
Clspn |
claspin |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CLSPN mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:138,850,119...138,885,037
Ensembl chr 5:138,850,128...138,885,034
|
|
G |
Clstn1 |
calsyntenin 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CLSTN1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 5:160,031,235...160,094,585
Ensembl chr 5:160,031,308...160,094,583
|
|
G |
Cltc |
clathrin heavy chain |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CLTC protein |
CTD |
PMID:21673325 |
|
NCBI chr10:71,517,661...71,574,591
Ensembl chr10:71,517,663...71,573,737
|
|
G |
Cma1 |
chymase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CMA1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233
|
|
G |
Cmpk2 |
cytidine/uridine monophosphate kinase 2 |
multiple interactions decreases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CMPK2 mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CMPK2 mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr 6:43,073,706...43,085,183
Ensembl chr 6:43,073,796...43,085,183
|
|
G |
Cngb3 |
cyclic nucleotide gated channel subunit beta 3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CNGB3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 5:32,746,988...32,995,121
Ensembl chr 5:32,746,988...32,995,121
|
|
G |
Cnnm3 |
cyclin and CBS domain divalent metal cation transport mediator 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNNM3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:38,755,374...38,770,740
Ensembl chr 9:38,755,390...38,770,740
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CNP protein |
CTD |
PMID:21673325 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Cnpy1 |
canopy FGF signaling regulator 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CNPY1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:7,182,311...7,191,408
Ensembl chr 4:7,136,533...7,189,761
|
|
G |
Cntln |
centlein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTLN mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:99,295,865...99,576,402
Ensembl chr 5:99,296,000...99,576,396
|
|
G |
Cntn2 |
contactin 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CNTN2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:43,942,868...43,975,973
Ensembl chr13:43,947,265...43,975,887
|
|
G |
Cntn4 |
contactin 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTN4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:138,624,584...139,622,499
Ensembl chr 4:139,099,152...139,621,090
|
|
G |
Cntnap2 |
contactin associated protein 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTNAP2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:74,109,455...76,366,434
Ensembl chr 4:74,109,472...76,362,027
|
|
G |
Cntrl |
centriolin |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CNTRL mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:18,428,147...18,500,362
Ensembl chr 3:18,428,103...18,500,380
|
|
G |
Cntrob |
centrobin, centriole duplication and spindle assembly protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CNTROB mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:54,022,523...54,047,793
Ensembl chr10:54,022,852...54,044,849
|
|
G |
Coa5 |
cytochrome C oxidase assembly factor 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COA5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:39,651,459...39,664,870
|
|
G |
Coch |
cochlin |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COCH mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109
|
|
G |
Cog5 |
component of oligomeric golgi complex 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of COG5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:48,242,470...48,545,185
Ensembl chr 6:48,242,482...48,529,009
|
|
G |
Cog7 |
component of oligomeric golgi complex 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of COG7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:176,489,795...176,549,455
Ensembl chr 1:176,489,791...176,549,455
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of COL11A1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col12a1 |
collagen type XII alpha 1 chain |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COL12A1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686
|
|
G |
Col23a1 |
collagen type XXIII alpha 1 chain |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of COL23A1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:35,549,090...35,839,152
Ensembl chr10:35,549,113...35,836,314
|
|
G |
Col24a1 |
collagen type XXIV alpha 1 chain |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COL24A1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:234,212,256...234,469,445
Ensembl chr 2:234,212,324...234,469,441
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of COL4A1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col4a3 |
collagen type IV alpha 3 chain |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of COL4A3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 9:83,875,849...84,004,955
Ensembl chr 9:83,875,561...84,001,895
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of COL6A3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of COMMD1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501
|
|
G |
Cops9 |
COP9 signalosome subunit 9 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COPS9 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:93,209,843...93,214,774
Ensembl chr 9:93,209,843...93,213,317
|
|
G |
Copz2 |
COPI coat complex subunit zeta 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COPZ2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:81,832,441...81,845,514
Ensembl chr10:81,832,418...81,845,514
|
|
G |
Coro2a |
coronin 2A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CORO2A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:60,825,630...60,881,917
Ensembl chr 5:60,828,247...60,859,035
|
|
G |
Cort |
cortistatin |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CORT mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:159,560,591...159,562,032
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COX4I1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Cox6b2 |
cytochrome c oxidase subunit 6B2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COX6B2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:69,094,009...69,095,312
|
|
G |
Cox7a1 |
cytochrome c oxidase subunit 7A1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of COX7A1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:85,422,162...85,447,530
Ensembl chr 1:85,441,871...85,445,151
|
|
G |
Cpa2 |
carboxypeptidase A2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPA2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:59,160,357...59,183,677
Ensembl chr 4:59,160,357...59,183,674
|
|
G |
Cpe |
carboxypeptidase E |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CPE mRNA |
CTD |
PMID:23829299 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cplx1 |
complexin 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CPLX1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr14:1,184,677...1,216,392
|
|
G |
Cpne1 |
copine 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CPNE1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:144,587,531...144,629,911
Ensembl chr 3:144,588,995...144,598,636
|
|
G |
Cpne9 |
copine family member 9 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPNE9 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:146,429,961...146,454,335
Ensembl chr 4:146,430,792...146,454,333
|
|
G |
Cpsf4l |
cleavage and polyadenylation specific factor 4-like |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPSF4L mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:98,741,816...98,756,069
Ensembl chr10:98,743,649...98,751,590
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CPT1C mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342
|
|
G |
Cptp |
ceramide-1-phosphate transfer protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CPTP mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:166,474,947...166,479,103
Ensembl chr 5:166,474,966...166,479,017
|
|
G |
Crb3 |
crumbs cell polarity complex component 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRB3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:1,898,531...1,903,860
Ensembl chr 9:1,896,623...1,903,859
|
|
G |
Crebl2 |
cAMP responsive element binding protein-like 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CREBL2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:167,673,359...167,699,299
Ensembl chr 4:167,673,315...167,699,292
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CREM mRNA |
CTD |
PMID:23829299 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRHR2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904
|
|
G |
Cripto |
cripto, EGF-CFC family member |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRIPTO mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:110,924,774...110,938,545
Ensembl chr 8:110,925,024...110,930,308
|
|
G |
Crisp2 |
cysteine-rich secretory protein 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CRISP2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 9:20,107,649...20,131,967
Ensembl chr 9:20,107,701...20,131,959
|
|
G |
Crlf1 |
cytokine receptor-like factor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRLF1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:18,924,722...18,936,049
Ensembl chr16:18,924,722...18,935,997
|
|
G |
Crtam |
cytotoxic and regulatory T cell molecule |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRTAM mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:41,340,117...41,377,381
Ensembl chr 8:41,340,837...41,377,343
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRYAB mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Crybb2 |
crystallin, beta B2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CRYBB2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:43,569,747...43,579,671
Ensembl chr12:43,569,747...43,579,671
|
|
G |
Crybg3 |
crystallin beta-gamma domain containing 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CRYBG3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:40,749,198...40,861,753
Ensembl chr11:40,749,214...40,861,752
|
|
G |
Csdc2 |
cold shock domain containing C2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CSDC2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:113,451,998...113,466,464
Ensembl chr 7:113,451,998...113,466,463
|
|
G |
Csmd3 |
CUB and Sushi multiple domains 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CSMD3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:78,747,322...80,066,466
Ensembl chr 7:78,748,480...80,066,369
|
|
G |
Csn3 |
casein kappa |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CSN3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:20,154,032...20,160,585
Ensembl chr14:20,154,032...20,160,587
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
affects expression |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl affects the expression of CSNK2A1 mRNA |
CTD |
PMID:21703328 |
|
NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Cspp1 |
centrosome and spindle pole associated protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CSPP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:9,077,161...9,192,402
Ensembl chr 5:9,077,161...9,193,377
|
|
G |
Csrp1 |
cysteine and glycine-rich protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CSRP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CST3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Cst6 |
cystatin E/M |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CST6 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:202,655,322...202,657,030
Ensembl chr 1:202,655,322...202,657,030
|
|
G |
Ctnnd1 |
catenin delta 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CTNND1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516
|
|
G |
Ctns |
cystinosin, lysosomal cystine transporter |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CTNS mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:57,801,551...57,817,213
Ensembl chr10:57,801,456...57,817,120
|
|
G |
Ctrc |
chymotrypsin C |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CTRC mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:154,147,314...154,156,540
Ensembl chr 5:154,147,316...154,156,528
|
|
G |
Ctxn1 |
cortexin 1 |
increases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CTXN1 mRNA [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CTXN1 mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr12:2,610,465...2,612,076
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CXCL12 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyct |
cytochrome c, testis |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYCT mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:61,290,090...61,297,158
Ensembl chr 3:60,913,562...61,297,158
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased activity of CYP1A1 protein |
CTD |
PMID:15093247 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases response to substance multiple interactions |
ISO |
CYP1A2 results in decreased susceptibility to 2,2',3',4,4',5-hexachlorobiphenyl 2,2',3',4,4',5-hexachlorobiphenyl promotes the reaction [AHR protein results in increased expression of CYP1A2]; [3,4,3',4'-tetrachlorobiphenyl co-treated with 3,4,5,3',4'-pentachlorobiphenyl co-treated with 3,4,5,3',4',5'-hexachlorobiphenyl co-treated with 2,3,3',4,4'-pentachlorobiphenyl co-treated with 2,3',4,4',5-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] promotes the reaction [AHR protein results in increased expression of CYP1A2 mRNA]; [AHR protein co-treated with CYP1A2 protein] affects the susceptibility to [3,4,3',4'-tetrachlorobiphenyl co-treated with 3,4,5,3',4'-pentachlorobiphenyl co-treated with 3,4,5,3',4',5'-hexachlorobiphenyl co-treated with 2,3,3',4,4'-pentachlorobiphenyl co-treated with 2,3',4,4',5-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] |
CTD |
PMID:20961953 PMID:21571617 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp20a1 |
cytochrome P450, family 20, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CYP20A1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:61,755,804...61,805,123
Ensembl chr 9:61,755,790...61,805,123
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of CYP27B1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression increases activity multiple interactions |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 mRNA; 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 protein 2,2',3',4,4',5-hexachlorobiphenyl results in increased activity of CYP2B1 protein NR1I2 gene mutant form inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 protein]; NR1I2 gene mutant form promotes the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 mRNA]; NR1I3 gene mutant form inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 mRNA]; NR1I3 gene mutant form inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 protein]; Okadaic Acid inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 mRNA]; Okadaic Acid inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP2B1 protein] |
CTD |
PMID:15093247 PMID:23770461 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases activity |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased activity of CYP2B2 protein |
CTD |
PMID:15093247 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2r1 |
cytochrome P450, family 2, subfamily r, polypeptide 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYP2R1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759
|
|
G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of CYP3A18 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr12:8,880,509...8,930,382
Ensembl chr12:8,880,528...8,930,381
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression multiple interactions |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA; 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP3A23-3A1 protein NR1I3 gene mutant form inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP3A23-3A1 mRNA]; Okadaic Acid inhibits the reaction [2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYP3A23-3A1 protein] |
CTD |
PMID:23770461 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYP46A1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760
|
|
G |
Cystm1 |
cysteine-rich transmembrane module containing 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CYSTM1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:27,945,862...28,013,509
Ensembl chr18:27,951,653...28,013,510
|
|
G |
Cyth4 |
cytohesin 4 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of CYTH4 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 7:110,152,232...110,176,726
Ensembl chr 7:110,152,272...110,176,741
|
|
G |
Dab1 |
DAB adaptor protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DAB1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552
|
|
G |
Dach1 |
dachshund family transcription factor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DACH1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:74,528,122...74,909,811
Ensembl chr15:74,529,208...74,909,922
|
|
G |
Dact1 |
dishevelled-binding antagonist of beta-catenin 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DACT1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:89,790,676...89,818,254
Ensembl chr 6:89,790,644...89,817,906
|
|
G |
Dact2 |
dishevelled-binding antagonist of beta-catenin 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DACT2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096
|
|
G |
Dag1 |
dystroglycan 1 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of DAG1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 8:108,890,926...108,955,611
Ensembl chr 8:108,890,929...108,952,325
|
|
G |
Dao |
D-amino-acid oxidase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DAO mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:42,592,342...42,613,046
Ensembl chr12:42,592,343...42,612,741
|
|
G |
Dapk1 |
death associated protein kinase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DAPK1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dbf4 |
DBF4-CDC7 kinase regulatory subunit |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DBF4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
|
|
G |
Dbn1 |
drebrin 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DBN1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dcaf17 |
DDB1 and CUL4 associated factor 17 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DCAF17 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:55,863,776...55,895,601
Ensembl chr 3:55,863,799...55,891,820
|
|
G |
Dck |
deoxycytidine kinase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DCK mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Dcps |
decapping enzyme, scavenger |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DCPS mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:33,468,669...33,524,407
Ensembl chr 8:33,415,671...33,524,389
|
|
G |
Dcx |
doublecortin |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DCX mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476
|
|
G |
Ddias |
DNA damage-induced apoptosis suppressor |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DDIAS mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DDR2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
|
|
G |
Ddt |
D-dopachrome tautomerase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DDT mRNA |
CTD |
PMID:25510870 |
|
NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
|
|
G |
Defb14 |
defensin beta 14 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DEFB14 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:70,663,443...70,668,473
Ensembl chr16:70,663,333...70,666,540
|
|
G |
Defb17 |
defensin beta 17 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DEFB41 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:20,880,246...20,883,875
|
|
G |
Dek |
DEK proto-oncogene |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of DEK mRNA |
CTD |
PMID:23829299 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Depdc1 |
DEP domain containing 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DEPDC1A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:248,684,508...248,717,951
Ensembl chr 2:248,684,523...248,717,951
|
|
G |
Deup1 |
deuterosome assembly protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DEUP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:12,380,300...12,442,649
Ensembl chr 8:12,380,302...12,442,199
|
|
G |
Dgkg |
diacylglycerol kinase, gamma |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DGKG mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:78,384,212...78,579,158
Ensembl chr11:78,384,458...78,577,212
|
|
G |
Dhx35 |
DEAH-box helicase 35 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of DHX35 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 3:147,450,178...147,507,473
Ensembl chr 3:147,450,163...147,507,451
|
|
G |
Dhx9 |
DExH-box helicase 9 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of DHX9 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
|
|
G |
Dip2b |
disco-interacting protein 2 homolog B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DIP2B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:131,174,575...131,350,417
Ensembl chr 7:131,174,567...131,349,092
|
|
G |
Diras2 |
DIRAS family GTPase 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DIRAS2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:12,730,040...12,761,511
Ensembl chr17:12,725,149...12,761,663
|
|
G |
Diras3 |
DIRAS family GTPase 3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DIRAS3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 6:130,524,972...130,526,186
Ensembl chr 6:130,524,742...130,530,825
|
|
G |
Disc1 |
DISC1 scaffold protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DISC1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778
|
|
G |
Disp2 |
dispatched RND transporter family member 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DISP2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:105,762,303...105,777,826
Ensembl chr 3:105,762,305...105,777,800
|
|
G |
Dkk4 |
dickkopf WNT signaling pathway inhibitor 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DKK4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:69,403,215...69,406,580
Ensembl chr16:69,402,989...69,406,580
|
|
G |
Dleu7 |
deleted in lymphocytic leukemia, 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DLEU7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:36,479,533...36,495,730
Ensembl chr15:36,479,534...36,495,697
|
|
G |
Dlg2 |
discs large MAGUK scaffold protein 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DLG2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180 co-treated with APP protein modified form] results in decreased expression of DLG4 protein |
CTD |
PMID:26480858 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dlgap3 |
DLG associated protein 3 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of DLGAP3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 5:139,491,972...139,562,625
Ensembl chr 5:139,492,947...139,562,625
|
|
G |
Dlgap5 |
DLG associated protein 5 |
multiple interactions decreases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DLGAP5 mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DLGAP5 mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dmd |
dystrophin |
multiple interactions decreases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DMD mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DMD mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dnah8 |
dynein, axonemal, heavy chain 8 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNAH8 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr20:8,692,939...8,946,780
Ensembl chr20:8,692,963...8,946,772
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DNAJB4 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Dnajb8 |
DnaJ heat shock protein family (Hsp40) member B8 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of DNAJB8 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 4:120,681,918...120,685,108
Ensembl chr 4:120,681,926...120,687,552
|
|
G |
Dnajc27 |
DnaJ heat shock protein family (Hsp40) member C27 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNAJC27 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:27,068,713...27,098,449
Ensembl chr 6:27,068,686...27,098,449
|
|
G |
Dnajc6 |
DnaJ heat shock protein family (Hsp40) member C6 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNAJC6 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448
|
|
G |
Dnajc8 |
DnaJ heat shock protein family (Hsp40) member C8 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DNAJC8 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 5:144,745,055...144,763,106
Ensembl chr 5:144,745,036...144,763,108
|
|
G |
Dnase2b |
deoxyribonuclease 2 beta |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNASE2B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:235,470,915...235,515,211
Ensembl chr 2:235,470,919...235,486,295
|
|
G |
Dnm1 |
dynamin 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DNM1 protein |
CTD |
PMID:21673325 |
|
NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:15,604,784...15,648,538
|
|
G |
Dnm2 |
dynamin 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DNM2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
|
|
G |
Dnm3 |
dynamin 3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DNM3 protein |
CTD |
PMID:21673325 |
|
NCBI chr13:74,359,043...74,838,135
Ensembl chr13:74,359,213...74,838,108
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DNMT3B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dnmt3l |
DNA methyltransferase 3 like |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DNMT3L mRNA |
CTD |
PMID:25510870 |
|
NCBI chr20:10,614,933...10,629,337
Ensembl chr20:10,614,934...10,629,516
|
|
G |
Doc2b |
double C2 domain beta |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DOC2B mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:60,628,029...60,653,267
Ensembl chr10:60,628,029...60,653,267
|
|
G |
Dock11 |
dedicator of cytokinesis 11 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DOCK11 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:115,131,720...115,314,854
Ensembl chr X:115,131,909...115,314,854
|
|
G |
Dock7 |
dedicator of cytokinesis 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DOCK7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:113,599,371...113,782,871
Ensembl chr 5:113,600,198...113,782,813
|
|
G |
Dok3 |
docking protein 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DOK3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:9,109,633...9,115,188
Ensembl chr17:9,109,597...9,115,188
|
|
G |
Dok5 |
docking protein 5 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DOK5 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 3:159,515,886...159,652,811
Ensembl chr 3:159,515,893...159,652,810
|
|
G |
Dok6 |
docking protein 6 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DOK6 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:82,572,762...83,015,951
Ensembl chr18:82,572,762...83,015,951
|
|
G |
Dpf3 |
double PHD fingers 3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DPF3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 6:102,841,403...103,125,558
Ensembl chr 6:102,846,029...103,125,493
|
|
G |
Dph5 |
diphthamide biosynthesis 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DPH5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:203,804,620...203,858,196
Ensembl chr 2:203,804,936...203,840,433
|
|
G |
Dpp10 |
dipeptidyl peptidase like 10 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DPP10 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:34,584,420...36,269,292
Ensembl chr13:34,595,868...36,269,292
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DPYSL3 mRNA; 2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DPYSL3 protein |
CTD |
PMID:21673325 PMID:23829299 |
|
NCBI chr18:35,374,427...35,480,228
Ensembl chr18:35,377,181...35,480,157
|
|
G |
Dpysl5 |
dihydropyrimidinase-like 5 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DPYSL5 protein |
CTD |
PMID:21673325 |
|
NCBI chr 6:25,575,104...25,659,422
Ensembl chr 6:25,575,104...25,659,422
|
|
G |
Draxin |
dorsal inhibitory axon guidance protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DRAXIN mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:158,530,149...158,563,457
Ensembl chr 5:158,530,342...158,564,483
|
|
G |
Drc3 |
dynein regulatory complex subunit 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DRC3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:45,149,094...45,200,659
Ensembl chr10:45,157,354...45,199,369
|
|
G |
Dscam |
DS cell adhesion molecule |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of DSCAM mRNA |
CTD |
PMID:23829299 |
|
NCBI chr11:35,921,924...36,507,100
Ensembl chr11:35,926,896...36,507,415
|
|
G |
Dscaml1 |
DS cell adhesion molecule-like 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DSCAML1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:45,740,298...46,057,322
Ensembl chr 8:45,740,298...46,057,320
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DSCC1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Dtna |
dystrobrevin, alpha |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DTNA mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:14,687,193...14,944,232
Ensembl chr18:14,587,852...14,944,261
|
|
G |
Dtnb |
dystrobrevin, beta |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DTNB mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:26,566,418...26,763,467
Ensembl chr 6:26,566,925...26,766,335
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DUSP14 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:68,936,483...68,966,347
Ensembl chr10:68,935,330...68,965,329
|
|
G |
Dusp19 |
dual specificity phosphatase 19 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DUSP19 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:65,538,424...65,554,465
Ensembl chr 3:65,538,420...65,553,534
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of DVL3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
Dyrk2 |
dual specificity tyrosine phosphorylation regulated kinase 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DYRK2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:54,348,724...54,381,363
Ensembl chr 7:54,349,610...54,380,106
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of E2F2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
E2f7 |
E2F transcription factor 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of E2F7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:46,150,533...46,192,739
Ensembl chr 7:46,151,293...46,192,734
|
|
G |
E2f8 |
E2F transcription factor 8 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of E2F8 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Ebf1 |
EBF transcription factor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EBF1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665
|
|
G |
Ebf2 |
EBF transcription factor 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EBF2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:41,435,509...41,634,403
Ensembl chr15:41,435,509...41,634,403
|
|
G |
Ebf3 |
EBF transcription factor 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EBF3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:191,996,726...192,114,593
Ensembl chr 1:191,996,730...192,114,359
|
|
G |
Ect2 |
epithelial cell transforming 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ECT2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of EEF1A1 protein |
CTD |
PMID:21673325 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of EEF2 protein |
CTD |
PMID:21673325 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Eef2k |
eukaryotic elongation factor-2 kinase |
decreases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of EEF2K mRNA [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EEF2K mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr 1:175,393,119...175,456,756
Ensembl chr 1:175,393,154...175,455,164
|
|
G |
Efcab11 |
EF-hand calcium binding domain 11 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EFCAB11 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:119,008,908...119,162,994
Ensembl chr 6:119,008,919...119,162,046
|
|
G |
Efna3 |
ephrin A3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EFNA3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
|
|
G |
Efs |
embryonal Fyn-associated substrate |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of EFS mRNA |
CTD |
PMID:23829299 |
|
NCBI chr15:28,392,417...28,403,016
Ensembl chr15:28,392,187...28,401,902
|
|
G |
Egf |
epidermal growth factor |
multiple interactions increases expression |
ISO EXP |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EGF mRNA 2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of EGF mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif4ebp3 |
eukaryotic translation initiation factor 4E binding protein 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EIF4EBP3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:28,263,089...28,268,033
Ensembl chr18:28,162,311...28,268,024
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of EIF5 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 6:130,589,162...130,597,656
Ensembl chr 6:130,589,143...130,597,656
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of EIF5B mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
|
|
G |
Elavl2 |
ELAV like RNA binding protein 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ELAVL2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:105,960,872...106,086,463
Ensembl chr 5:105,960,875...106,109,097
|
|
G |
Elf4 |
E74 like ETS transcription factor 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ELF4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:127,587,401...127,639,063
Ensembl chr X:127,590,650...127,630,200
|
|
G |
Elk4 |
ETS transcription factor ELK4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ELK4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:43,451,130...43,475,035
Ensembl chr13:43,435,843...43,475,035
|
|
G |
Elmo3 |
engulfment and cell motility 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ELMO3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:33,181,952...33,186,399
Ensembl chr19:33,182,036...33,186,410
|
|
G |
Eme1 |
essential meiotic structure-specific endonuclease 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of EME1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435
|
|
G |
Eml2 |
EMAP like 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of EML2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:78,827,595...78,859,342
Ensembl chr 1:78,828,080...78,859,341
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ENC1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Eno1 |
enolase 1 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ENO1 protein |
CTD |
PMID:21673325 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336 Ensembl chr 3:160,719,951...160,731,336
|
|
G |
Eno2 |
enolase 2 |
increases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of ENO2 protein [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ENO2 mRNA |
CTD |
PMID:21673325 PMID:25510870 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ENPP2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Entpd4 |
ectonucleoside triphosphate diphosphohydrolase 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ENTPD4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:44,630,878...44,658,654
Ensembl chr15:44,630,873...44,658,706
|
|
G |
Eomes |
eomesodermin |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EOMES mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:118,181,340...118,189,186
Ensembl chr 8:118,181,777...118,188,316
|
|
G |
Ep400 |
E1A binding protein p400 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EP400 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:45,891,886...46,002,523
Ensembl chr12:45,891,916...45,998,861
|
|
G |
Epb41l1 |
erythrocyte membrane protein band 4.1-like 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of EPB41L1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 3:144,929,195...145,052,723
Ensembl chr 3:144,984,640...145,052,721
|
|
G |
Epb41l5 |
erythrocyte membrane protein band 4.1 like 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EPB41L5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360
|
|
G |
Epha5 |
EPH receptor A5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EPHA5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:23,653,393...24,020,129
Ensembl chr14:23,653,393...24,017,317
|
|
G |
Eppin |
epididymal peptidase inhibitor |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EPPIN mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:153,312,396...153,319,310
Ensembl chr 3:153,312,396...153,319,310
|
|
G |
Eps8l2 |
EPS8-like 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of EPS8L2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:196,446,260...196,471,544
Ensembl chr 1:196,446,287...196,471,541
|
|
G |
Ercc6l |
ERCC excision repair 6 like, spindle assembly checkpoint helicase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ERCC6L mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:67,245,414...67,261,222
Ensembl chr X:67,245,414...67,280,756
|
|
G |
Eri1 |
exoribonuclease 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ERI1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:56,724,101...56,744,228
Ensembl chr16:56,724,115...56,744,226
|
|
G |
Eri2 |
ERI1 exoribonuclease family member 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ERI2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:174,140,831...174,168,757
Ensembl chr 1:174,141,993...174,168,665
|
|
G |
Erp27 |
endoplasmic reticulum protein 27 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ERP27 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 4:169,804,656...169,821,660
Ensembl chr 4:169,804,658...169,821,660
|
|
G |
Esco1 |
establishment of sister chromatid cohesion N-acetyltransferase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ESCO1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:1,630,560...1,686,803
Ensembl chr18:1,631,954...1,686,942
|
|
G |
Esco2 |
establishment of sister chromatid cohesion N-acetyltransferase 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ESCO2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306
|
|
G |
Espl1 |
extra spindle pole bodies like 1, separase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of ESPL1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:133,424,027...133,450,984
Ensembl chr 7:133,424,130...133,450,984
|
|
G |
Esrrb |
estrogen-related receptor beta |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ESRRB mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:106,007,701...106,163,136
Ensembl chr 6:106,008,095...106,160,791
|
|
G |
Esyt3 |
extended synaptotagmin 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ESYT3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:99,870,418...99,917,298
Ensembl chr 8:99,871,149...99,917,232
|
|
G |
Etnppl |
ethanolamine-phosphate phospho-lyase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ETNPPL mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:219,173,048...219,194,646
Ensembl chr 2:219,172,978...219,192,212
|
|
G |
Etv1 |
ETS variant transcription factor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of ETV1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775
|
|
G |
Etv2 |
ETS variant transcription factor 2 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of ETV2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:85,890,562...85,894,025
Ensembl chr 1:85,890,559...85,893,431
|
|
G |
Exo1 |
exonuclease 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EXO1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Exosc2 |
exosome component 2 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of EXOSC2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 3:14,962,930...14,973,645
Ensembl chr 3:14,962,917...14,973,575
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of EZH2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
Ezr |
ezrin |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of EZR protein |
CTD |
PMID:21673325 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F11 |
coagulation factor XI |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of F11 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr16:46,987,988...47,009,015
Ensembl chr16:46,986,107...47,008,437
|
|
G |
F2 |
coagulation factor II, thrombin |
affects expression |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl affects the expression of F2 mRNA |
CTD |
PMID:21703328 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of F2R mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F5 |
coagulation factor V |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of F5 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl promotes the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 protein] |
CTD |
PMID:29704545 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp9 |
fatty acid binding protein 9 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FABP9 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873
|
|
G |
Fadd |
Fas associated via death domain |
affects expression |
ISO |
2,2',3',4,4',5-hexachlorobiphenyl affects the expression of FADD mRNA |
CTD |
PMID:21703328 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fads3 |
fatty acid desaturase 3 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of FADS3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:206,685,667...206,702,538
Ensembl chr 1:206,685,894...206,704,769
|
|
G |
Faim2 |
Fas apoptotic inhibitory molecule 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAIM2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 7:130,632,368...130,659,353
Ensembl chr 7:130,633,348...130,659,168
|
|
G |
Fam107a |
family with sequence similarity 107, member A |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of FAM107A mRNA |
CTD |
PMID:23829299 |
|
NCBI chr15:16,608,362...16,630,398
Ensembl chr15:16,607,205...16,630,396
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of FAM111A mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
|
|
G |
Fam13c |
family with sequence similarity 13, member C |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAM13C mRNA |
CTD |
PMID:25510870 |
|
NCBI chr20:18,065,625...18,187,792
Ensembl chr20:18,065,628...18,187,592
|
|
G |
Fam217b |
family with sequence similarity 217, member B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAM217B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:165,505,574...165,515,273
Ensembl chr 3:165,501,532...165,513,377
|
|
G |
Fam228a |
family with sequence similarity 228, member A |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of FAM228A mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 6:27,727,982...27,750,140
Ensembl chr 6:27,727,984...27,750,061
|
|
G |
Fam234a |
family with sequence similarity 234, member A |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of FAM234A mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:15,232,267...15,263,529
Ensembl chr10:15,232,278...15,263,488
|
|
G |
Fam43b |
family with sequence similarity 43, member B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAM43B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:150,610,656...150,613,054
Ensembl chr 5:150,611,609...150,612,601
|
|
G |
Fam53b |
family with sequence similarity 53, member B |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FAM53B mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:187,500,061...187,591,186
Ensembl chr 1:187,500,066...187,591,186
|
|
G |
Fam83f |
family with sequence similarity 83, member F |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of FAM83F mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 7:112,211,164...112,240,454
Ensembl chr 7:112,211,164...112,240,452
|
|
G |
Fanca |
FA complementation group A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FANCA mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:51,304,126...51,362,586
Ensembl chr19:51,304,021...51,362,527
|
|
G |
Fancd2 |
FA complementation group D2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FANCD2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Fanci |
FA complementation group I |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FANCI mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Farsa |
phenylalanyl-tRNA synthetase subunit alpha |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FARSA mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980
|
|
G |
Fastkd2 |
FAST kinase domains 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FASTKD2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 9:65,166,148...65,188,184
Ensembl chr 9:65,168,228...65,188,174
|
|
G |
Fat2 |
FAT atypical cadherin 2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FAT2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:39,364,072...39,456,324
Ensembl chr10:39,364,073...39,456,216
|
|
G |
Fat3 |
FAT atypical cadherin 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FAT3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:12,691,470...13,274,336
Ensembl chr 8:12,694,019...13,273,135
|
|
G |
Fbl |
fibrillarin |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of FBL mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932
|
|
G |
Fbln1 |
fibulin 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of FBLN1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbxo5 |
F-box protein 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FBXO5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437
|
|
G |
Fcgbpl1 |
Fc fragment of IgG binding protein-like 1 |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of FCGBPL1 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 1:83,424,788...83,462,802
Ensembl chr 1:83,424,788...83,462,799
|
|
G |
Fcgr1a |
Fc gamma receptor 1A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FCGR1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:183,851,075...183,860,077
Ensembl chr 2:183,851,077...183,859,994
|
|
G |
Fcrl5 |
Fc receptor-like 5 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FCRL5 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:172,881,763...172,912,912
Ensembl chr 2:172,881,448...172,913,148
|
|
G |
Fcrla |
Fc receptor-like A |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of FCRLA mRNA |
CTD |
PMID:23829299 |
|
NCBI chr13:83,160,453...83,170,170
Ensembl chr13:83,160,398...83,170,762
|
|
G |
Fer1l4 |
fer-1-like family member 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FER1L4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:144,536,099...144,571,634
Ensembl chr 3:144,536,099...144,571,634
|
|
G |
Fgd1 |
FYVE, RhoGEF and PH domain containing 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGD1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:20,023,746...20,066,734
Ensembl chr X:20,023,746...20,066,566
|
|
G |
Fgd4 |
FYVE, RhoGEF and PH domain containing 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGD4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:84,399,989...84,551,013
Ensembl chr11:84,399,816...84,546,972
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf12 |
fibroblast growth factor 12 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF12 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr11:71,997,151...72,564,757
Ensembl chr11:71,997,099...72,562,607
|
|
G |
Fgf14 |
fibroblast growth factor 14 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF14 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:101,045,033...101,679,888
Ensembl chr15:101,045,036...101,679,900
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF21 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgf3 |
fibroblast growth factor 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FGF3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:200,001,162...200,005,539
Ensembl chr 1:200,001,261...200,005,187
|
|
G |
Fgf6 |
fibroblast growth factor 6 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF6 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:159,854,913...159,863,447
Ensembl chr 4:159,854,913...159,863,447
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGF7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of FGFR3 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fggy |
FGGY carbohydrate kinase domain containing |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FGGY mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 5:110,398,866...110,786,019
Ensembl chr 5:110,398,863...110,786,017
|
|
G |
Fhip1a |
FHF complex subunit HOOK interacting protein 1A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FHIP1A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:171,016,951...171,265,715
Ensembl chr 2:171,021,246...171,265,848
|
|
G |
Fignl1 |
fidgetin-like 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FIGNL1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:86,368,670...86,381,728
Ensembl chr14:86,368,675...86,377,455
|
|
G |
Fitm1 |
fat storage-inducing transmembrane protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FITM1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr15:29,064,746...29,066,015
Ensembl chr15:29,064,707...29,066,015
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FKBP1A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743
|
|
G |
Fkbp4 |
FKBP prolyl isomerase 4 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of FKBP4 protein |
CTD |
PMID:21673325 |
|
NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833
|
|
G |
Flna |
filamin A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FLNA mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FLT1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fn1 |
fibronectin 1 |
increases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of FN1 mRNA [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FN1 mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fn3krp |
fructosamine-3-kinase-related protein |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of FN3KRP mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:106,688,413...106,697,137
Ensembl chr10:106,688,439...106,697,134
|
|
G |
Fnbp1 |
formin binding protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FNBP1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:14,309,067...14,424,378
Ensembl chr 3:14,309,640...14,424,881
|
|
G |
Fnbp1l |
formin binding protein 1-like |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FNBP1L mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:210,647,241...210,748,203
Ensembl chr 2:210,647,246...210,738,455
|
|
G |
Fnbp4 |
formin binding protein 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FNBP4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:76,733,012...76,763,077
Ensembl chr 3:76,733,027...76,763,079
|
|
G |
Fndc1 |
fibronectin type III domain containing 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FNDC1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:47,281,839...47,364,247
Ensembl chr 1:47,281,844...47,364,259
|
|
G |
Folr1 |
folate receptor alpha |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOLR1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOS protein |
CTD |
PMID:21190954 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxl2 |
forkhead box L2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOXL2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:99,512,971...99,514,500
Ensembl chr 8:99,513,303...99,514,427
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FOXM1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxp1 |
forkhead box P1 |
increases expression multiple interactions |
EXP ISO |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of FOXP1 mRNA [2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FOXP1 mRNA |
CTD |
PMID:23829299 PMID:25510870 |
|
NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258
|
|
G |
Foxp2 |
forkhead box P2 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FOXP2 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683
|
|
G |
Frmd4a |
FERM domain containing 4A |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FRMD4A mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:73,667,787...74,258,487
Ensembl chr17:73,667,789...74,258,687
|
|
G |
Frmpd3 |
FERM and PDZ domain containing 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FRMPD3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:103,964,168...104,113,864
Ensembl chr X:104,043,194...104,111,968
|
|
G |
Frmpd4 |
FERM and PDZ domain containing 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FRMPD4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:25,853,849...26,814,642
Ensembl chr X:25,853,934...26,814,637
|
|
G |
Fry |
FRY microtubule binding protein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FRY mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:4,493,890...4,887,118
Ensembl chr12:4,493,891...4,799,116
|
|
G |
Fryl |
FRY like transcription coactivator |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FRYL mRNA |
CTD |
PMID:25510870 |
|
NCBI chr14:34,956,623...35,189,738
Ensembl chr14:34,956,620...35,190,222
|
|
G |
Fscn2 |
fascin actin-bundling protein 2, retinal |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of FSCN2 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr10:105,634,783...105,641,322
Ensembl chr10:105,634,783...105,641,322
|
|
G |
Ftsj1 |
FtsJ RNA 2'-O-methyltransferase 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of FTSJ1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:14,243,684...14,256,555
Ensembl chr X:14,244,050...14,252,030
|
|
G |
Fuom |
fucose mutarotase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FUOM mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:194,888,535...194,893,046
Ensembl chr 1:194,886,709...194,893,046
|
|
G |
Fut7 |
fucosyltransferase 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FUT7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:8,237,687...8,242,273
Ensembl chr 3:8,239,384...8,242,260
|
|
G |
Fut8 |
fucosyltransferase 8 |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of FUT8 mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 6:95,949,246...96,176,677
Ensembl chr 6:95,949,991...96,176,677
|
|
G |
Fxyd1 |
FXYD domain-containing ion transport regulator 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FXYD1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:86,287,165...86,291,278
|
|
G |
G2e3 |
G2/M-phase specific E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of G2E3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 6:68,763,847...68,795,305
Ensembl chr 6:68,764,185...68,793,924
|
|
G |
Gaa |
alpha glucosidase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GAA mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:104,529,673...104,546,836
Ensembl chr10:104,529,747...104,546,836
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
multiple interactions |
EXP |
[2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GABBR2 mRNA |
CTD |
PMID:21277884 |
|
NCBI chr 5:60,947,517...61,288,104
Ensembl chr 5:60,947,526...61,288,104
|
|
G |
Gabpa |
GA binding protein transcription factor subunit alpha |
increases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of GABPA mRNA |
CTD |
PMID:23829299 |
|
NCBI chr11:23,888,586...23,917,612
Ensembl chr11:23,888,815...23,917,605
|
|
G |
Gabpb1 |
GA binding protein transcription factor subunit beta 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GABPB1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:113,879,972...113,924,742
Ensembl chr 3:113,879,973...113,923,696
|
|
G |
Gabrp |
gamma-aminobutyric acid type A receptor subunit pi |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GABRP mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:18,143,031...18,169,595
Ensembl chr10:18,143,038...18,169,516
|
|
G |
Gadl1 |
glutamate decarboxylase-like 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GADL1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 8:115,605,609...115,785,676
Ensembl chr 8:115,605,873...115,784,410
|
|
G |
Galns |
galactosamine (N-acetyl)-6-sulfatase |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GALNS mRNA |
CTD |
PMID:25510870 |
|
NCBI chr19:50,628,639...50,662,477
Ensembl chr19:50,628,552...50,662,246
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GALNT15 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014
|
|
G |
Galnt17 |
polypeptide N-acetylgalactosaminyltransferase 17 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GALNT17 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr12:25,323,230...25,781,897
Ensembl chr12:25,322,701...25,781,290
|
|
G |
Galntl6 |
polypeptide N-acetylgalactosaminyltransferase-like 6 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GALNTL6 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr16:31,192,880...32,443,979
Ensembl chr16:31,186,462...32,441,960
|
|
G |
Galr1 |
galanin receptor 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GALR1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr18:75,772,021...75,787,577
Ensembl chr18:75,772,023...75,787,577
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of GAPDH protein |
CTD |
PMID:21673325 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gapdhs |
glyceraldehyde-3-phosphate dehydrogenase, spermatogenic |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GAPDHS mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 1:85,979,096...85,994,153
Ensembl chr 1:85,979,098...85,993,640
|
|
G |
Gar1 |
GAR1 ribonucleoprotein |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GAR1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:218,375,231...218,382,509
Ensembl chr 2:218,375,353...218,382,524
|
|
G |
Garnl3 |
GTPase activating Rap/RanGAP domain-like 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GARNL3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 3:16,288,718...16,432,308
Ensembl chr 3:16,288,719...16,430,837
|
|
G |
Gas7 |
growth arrest specific 7 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GAS7 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276
|
|
G |
Gata1 |
GATA binding protein 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GATA1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GATA3 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gatad1 |
GATA zinc finger domain containing 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GATAD1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:30,507,530...30,519,107
Ensembl chr 4:30,507,538...30,519,107
|
|
G |
Gbp4 |
guanylate binding protein 4 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of GBP4 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879
|
|
G |
Gbx1 |
gastrulation brain homeobox 1 |
multiple interactions |
ISO |
[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of GBX1 mRNA |
CTD |
PMID:25510870 |
|
NCBI chr 4:10,645,957...10,672,486
Ensembl chr 4:10,645,957...10,672,486
|
|
G |
Gcg |
glucagon |
decreases expression |
EXP |
2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of GCG mRNA |
CTD |
PMID:23829299 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
| |